Compare · head to head
Aclaris Therapeutics vs Syndax Pharmaceuticals
Syndax Pharmaceuticals ranks higher overall — 360 rank 59 vs 28.
Syndax Pharmaceuticals leads on Quality (42 vs 32), Growth (66 vs 45) and Safety (52 vs 45). The two are close on Value and Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Biotechnology |
| Size | Small | Small |
| ISIN | US00461U1051 | US87164F1057 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 28 | 59 |
| Value | 42 | 41 |
| Quality | 32 | 42 |
| Growth | 45 | 66 |
| Safety | 45 | 52 |
| Sentiment | 62 | 58 |
| Quality details | ||
| Profitability | 19 | 20 |
| Cash Truth | 46 | 63 |
Aclaris Therapeutics vs Nurix TherapeuticsAclaris Therapeutics vs XencorAclaris Therapeutics vs Regeneron PharmaceuticalsAclaris Therapeutics vs Spero TherapeuticsAdd a third stock →
Full analyses: Aclaris Therapeutics · Syndax Pharmaceuticals
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100